Objective：To investigate the association between the X-ray repair cross complementing（XRCC） group 5, XRCC6 and XRCC7 polymorphisms and risk of acute myeloid leukemia（AML）. Methods：This hospital-based case-contro...Objective：To investigate the association between the X-ray repair cross complementing（XRCC） group 5, XRCC6 and XRCC7 polymorphisms and risk of acute myeloid leukemia（AML）. Methods：This hospital-based case-control study included 120 AML patients and 210 cancer-free controls in a Chinese population. Three polymorphisms of XRCC5, XRCC6 and XRCC7 were genotyped using the polymerase chain reaction（PCR） or polymerase chain reaction-restriction fragment length polymorphism（PCR-RFLP） method. Results： We found that there was a significant decrease in risk of AML associated with the XRCC6 -61 CG/GG genotype（adjusted odd ratio （OR） = 0.55; 95% confident interval（CI） = 0.34-0.89） compared with the -61CC genotype. For the novel tandem repeat polymorphism （VNTR） in the XRCC5 promoter, we found when the XRCC5 six genotypes were dichotomized（i.e., 2R/2R, 2R/1R versus 2R/0R, 1R/1R, 1R/0R and 0R/0R）, the latter group was associated with increased risk of AML（adjusted OR = 1.67; 95% CI = 1.00-2.79） compared to 2R/ 2R＋2R/1R genotype. However, the XRCC7 6721G〉T polymorphism had no effect on risk of AML. Conclusion：The XRCC6 -61C 〉 G and XRCC5 2R/1R/0R polymorphisms, but not XRCC7 6721G 〉 T polymorphism, could play an important role in the development of AML. Larger scale studies with more detailed data on environment exposure are needed to verify these findings.展开更多
背景与目的:基因多态预测肿瘤化疗药物敏感性对肿瘤个体化治疗具有重要意义。本研究旨在探讨DNA修复基因XRCC1 codon194及399位点基因多态性与非小细胞肺癌长春瑞滨加顺铂(vinorelbine and cisplatin,NVB and DDP,NP)方案化疗敏感性的...背景与目的:基因多态预测肿瘤化疗药物敏感性对肿瘤个体化治疗具有重要意义。本研究旨在探讨DNA修复基因XRCC1 codon194及399位点基因多态性与非小细胞肺癌长春瑞滨加顺铂(vinorelbine and cisplatin,NVB and DDP,NP)方案化疗敏感性的关系。方法:采用聚合酶链反应-限制性片段长度多态性技术检测164例非小细胞肺癌患者外周血DNAXRCC1194和399位点的多态性。选择NP方案化疗,化疗两周期后评价疗效,并分析化疗敏感性与基因多态性的关系。结果:携带XRCC1基因Codon194C/T+T/T基因型者化疗有效率(41.8%)是C/C基因型者(26.0%)的2.038倍(P=0.036,95%CI=1.044-3.976)。携带XRCC1基因Codon399G/G、A/G、A/A型的患者化疗有效率(37.1%,34.6%,14.3%)之间的差异无统计学意义(P>0.05)。展开更多
基金supported in part by National Natural Science Foundation of China(30571541)Natural Science Foundation of Jiangsu Province(BK2006233,BK2005161)+1 种基金Medicine Foundation of Jiangsu Province(H200506)Creative Science Foundation of Nanjing Medical University(CX2004002)
文摘Objective：To investigate the association between the X-ray repair cross complementing（XRCC） group 5, XRCC6 and XRCC7 polymorphisms and risk of acute myeloid leukemia（AML）. Methods：This hospital-based case-control study included 120 AML patients and 210 cancer-free controls in a Chinese population. Three polymorphisms of XRCC5, XRCC6 and XRCC7 were genotyped using the polymerase chain reaction（PCR） or polymerase chain reaction-restriction fragment length polymorphism（PCR-RFLP） method. Results： We found that there was a significant decrease in risk of AML associated with the XRCC6 -61 CG/GG genotype（adjusted odd ratio （OR） = 0.55; 95% confident interval（CI） = 0.34-0.89） compared with the -61CC genotype. For the novel tandem repeat polymorphism （VNTR） in the XRCC5 promoter, we found when the XRCC5 six genotypes were dichotomized（i.e., 2R/2R, 2R/1R versus 2R/0R, 1R/1R, 1R/0R and 0R/0R）, the latter group was associated with increased risk of AML（adjusted OR = 1.67; 95% CI = 1.00-2.79） compared to 2R/ 2R＋2R/1R genotype. However, the XRCC7 6721G〉T polymorphism had no effect on risk of AML. Conclusion：The XRCC6 -61C 〉 G and XRCC5 2R/1R/0R polymorphisms, but not XRCC7 6721G 〉 T polymorphism, could play an important role in the development of AML. Larger scale studies with more detailed data on environment exposure are needed to verify these findings.
文摘背景与目的:基因多态预测肿瘤化疗药物敏感性对肿瘤个体化治疗具有重要意义。本研究旨在探讨DNA修复基因XRCC1 codon194及399位点基因多态性与非小细胞肺癌长春瑞滨加顺铂(vinorelbine and cisplatin,NVB and DDP,NP)方案化疗敏感性的关系。方法:采用聚合酶链反应-限制性片段长度多态性技术检测164例非小细胞肺癌患者外周血DNAXRCC1194和399位点的多态性。选择NP方案化疗,化疗两周期后评价疗效,并分析化疗敏感性与基因多态性的关系。结果:携带XRCC1基因Codon194C/T+T/T基因型者化疗有效率(41.8%)是C/C基因型者(26.0%)的2.038倍(P=0.036,95%CI=1.044-3.976)。携带XRCC1基因Codon399G/G、A/G、A/A型的患者化疗有效率(37.1%,34.6%,14.3%)之间的差异无统计学意义(P>0.05)。
